You Spoke and Congress Acted
March 15, 2022
Each year, Congress must allocate funds for the following year’s budget, and every year, we lead the...
FDA
LRA Writes President Supporting Dr. Janet Woodcock for FDA Commissioner
March 31, 2021
As part of the LRA's mission to accelerate development and availability of much-needed new diagnostics and treatments...
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
NEW YORK, NY. January...
Over Half of People with Lupus Would Take COVID-19 Vaccine, Shows LRA Survey
Updated January 4, 2021
New York, NY– December 16, 2020. More than half of people with lupus (54%) are willing...
FDA Revoked Emergency Use Approval of Hydroxychloroquine for COVID-19
June 15, 2020
The U.S. Food and Drug Administration announced June 15 that it revoked approval called emergency use authorization...
Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020
The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application...
Lupus and COVID-19: What You Need to Know – LIVE WEBCAST May 21 at 6 PM ET
Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine...
Lupus Research Alliance Thanks FDA for Responsiveness Re Letter Citing Plaquenil Shortages
May 7, 2020
The Lupus Research Alliance held an informative call with the Food and Drug Administration (FDA) in response...
Actions from Pharmaceutical Companies to Preserve Hydroxychloroquine (Plaquenil) Supply
March 30, 2020
The rheumatology community has been in discussions with the U.S. Food and Drug Administration and many pharmaceutical...